Correlation Engine 2.0
Clear Search sequence regions


  • 1A9 (3)
  • acid reflux (3)
  • adult (1)
  • alleles (2)
  • allografts (1)
  • factor (1)
  • female (1)
  • genes (2)
  • genotypes (2)
  • HNF 1α (1)
  • hnf1a protein, human (1)
  • HNF1α (4)
  • humans (1)
  • male (1)
  • mycophenolic acid (9)
  • nuclear factor 1 (2)
  • patients (4)
  • protein human (1)
  • renal transplant (1)
  • scale (6)
  • UGT1 (1)
  • UGT1A8 (4)
  • UGT1A9 (3)
  • Sizes of these terms reflect their relevance to your search.

    Mycophenolic acid (MPA), a widely used immunosuppressant, has a complex metabolism that involves a number of enzymes. Some of its metabolites are thought to be the cause of gastrointestinal (GI) side effects. In this study, we investigated whether polymorphisms of UDP-glucuronosyltransferases (UGT1) A8, 1A9, and hepatocyte nuclear factor (HNF1α) genes or pharmacokinetic parameters of mycophenolic acid (MPA) were associated with the severity of GI symptoms in patients receiving MPA therapy. A total of 109 kidney transplant patients taking mycophenolic acid (MPA) derivatives were genotyped for UGT1A8, 1A9 and HNF1α genes. Among these, a total of 15 patients were participants in the pharmacokinetic study. Severity of GI symptoms was assessed using a validated Gastrointestinal Symptom Rating Scale (GSRS). The overall and subscale GSRS scores were measured at 1 week (baseline), 2 weeks, 3 months and 6 months post-transplantation. In the case of the pharmacokinetic study, EC-MPS was administered and a total of nine blood samples were obtained at -1, 0, 0.5, 1, 2, 4, 6, 8, and 12h. Genotypes of UGT1A8 were significantly associated with the overall GSRS scores at week 1 (p=0.02) and week 2 (p=0.036). Subscales were only statistically significant for constipation at week 1 (p=0.002) and indigestion at week 2 (p=0.02), while UGT1A9 was only significant for the constipation at week 1 (p=0.04). HNF1α genotypes were significantly different at week 1 in the overall GSRS (p=0.004), and for abdominal pain (p=0.04), acid reflux (p=0.036) and constipation subscales (p=0.04). In addition, abdominal pain was statistically significantly different at 3 months and 6 months after transplantation (p=0.03 and 0.02, respectively). In the case of the pharmacokinetic study, we have found some correlations between MPAC0 and constipation (p=0.02) where MPAAUC was correlated with acid reflux (p=0.02) and constipation (p=0.012), MPAGCL/F was correlated to acid reflux, indigestion, constipation and the sum of the GSRS scores (p=0.037, p=0.032, p=0.033 and p=0.04, respectively). Multinomial regression analysis for MPAGCL/F showed a statistical significance for the subscale indigestion and the sum of the GSRS (p=0.033 and p=0.037, respectively). Our data suggests that among patients receiving MPA the UGT1A9 alleles might play a role in determining the severity of early GI side effects, while the HNF1α allele appears to be associated with a later effect as well as early side effects. Our data also showed that some kinetic parameters might predict MPA side effects. Copyright © 2013 Elsevier B.V. All rights reserved.

    Citation

    Don Vu, Eglis Tellez-Corrales, Jaewook Yang, Yasir Qazi, Tariq Shah, Robert Naraghi, Ian V Hutchinson, David I Min. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1α and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Transplant immunology. 2013 Dec;29(1-4):155-61

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 23721685

    View Full Text